Your browser doesn't support javascript.
loading
Myasthenia gravis and specific immunotherapy: monoclonal antibodies.
Cai, Xiao-Jun; Li, Zai-Wang; Xi, Jian-Ying; Song, Hui-Zhu; Liu, Jue; Zhu, Wen-Hua; Guo, Yi; Jiao, Zheng.
Afiliação
  • Cai XJ; Department of Clinical Pharmacy, Huashan Hospital, Fudan University, Shanghai, P. R. China.
  • Li ZW; Department of Pharmacy, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, P. R. China.
  • Xi JY; Department of Neurology, Shenzhen People's Hospital, the Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, P. R. China.
  • Song HZ; Department of Neurology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, P. R. China.
  • Liu J; Department of Neurology, Huashan Hospital, Fudan University, Shanghai, P. R. China.
  • Zhu WH; Department of Pharmacy, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, P. R. China.
  • Guo Y; Department of Clinical Pharmacy, Huashan Hospital, Fudan University, Shanghai, P. R. China.
  • Jiao Z; Department of Neurology, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Ann N Y Acad Sci ; 1452(1): 18-33, 2019 09.
Article em En | MEDLINE | ID: mdl-31393614
Myasthenia gravis (MG) is an acquired autoimmune disease affecting the postsynaptic membrane of neuromuscular junctions and characterized by antibody-mediated T cell dependence and complement involvement. Cholinesterase inhibitors (e.g., pyridostigmine bromide), glucocorticoids, and azathioprine are currently recommended as first-line treatments for MG, though they have limitations, including potential toxicity and ineffectiveness in patients with refractory MG. In recent years, owing to an increasing understanding of MG pathogenesis the development and execution of clinical trials with novel biologics, including monoclonal antibodies (mAbs) that have demonstrated higher safety and more specificity, provide new opportunities for the treatment of MG. In this article, we review recent advances in MG pathogenesis and the mAbs that have been used for target-specific MG therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Anticorpos Monoclonais / Miastenia Gravis Limite: Humans Idioma: En Revista: Ann N Y Acad Sci Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Anticorpos Monoclonais / Miastenia Gravis Limite: Humans Idioma: En Revista: Ann N Y Acad Sci Ano de publicação: 2019 Tipo de documento: Article